GAfPA Statement on United States-Mexico-Canada Agreement
Patients who are eager for the next generation of treatments and cures will be well served by the United States-Mexico-Canada Agreement. This agreement provides intellectual property protections that promote patient access to innovative medicine, clearing the way for new treatments for cancer, Alzheimer’s, diabetes and many other conditions.
